Efficacy assessments
Erythema, hyperpigmentation, Acne lesions, Pain, hypopigmentation, erythema, pain, acne lesions, acne, Acne
ERYTHEMA, SCAR, HYPERPIGMENTATION, HYPOPIGMENTATION, ERYTHEMA, ADVERSE EFFECTS, ACNE, ACNE, SCARRING
Primary assessment was done by count of acne lesions at 1 month after the last session [Secondary assessment was performed through severity grading by the Global Acne Severity Scale (GEA Scale), acne lesions improvement percentage, and patient’s satisfaction [Clinical images were taken by an iPhone 6 s Plus (12 mega pixel, f/2.2 mm, LED flash, China) at baseline, each session, 1 month after the last session, and a 3-month follow-up after the last treatment.Acne lesions counting [Patient Global Impression of Change (PGIC), a 7-point scale representing a patient’s rating of overall improvement was conducted [Pain level was evaluated by the patients after each treatment via a 10-point visual analog scale (VAS 1 = no pain, 10 = worst pain ever felt).The degree of clinical improvement of facial pore size was recorded according to the Quartile improvement scale [Any changes in scar grading were documented using the Goodman and Baron qualitative and quantitative acne scarring grading system [The expected adverse effects are the following: (a) Erythema that lasts longer than 48 h which is graded on a three-point scale (at level of 0; “no erythema,” at level of 3; “severe erythema”). (b) Post laser hyperpigmentation (a score of 0 indicates no hyperpigmentation following laser therapy, whereas a score of 1 indicates the existence of hyperpigmentation). (c) Post laser hypopigmentation (a score of 0 shows the lack of hypopigmentation after laser treatment, whereas a value of 1 indicates the existence of hypopigmentation).Recurrence was defined as appearance of same lesions after the whole therapy or the development of novel lesions. Patients’ satisfaction levels were assessed through the VAS (0–10; 0: “not satisfied,” 10: “completely satisfied”).